Operating CF
$8.29B
Capex
−$1.54B
Free Cash Flow
$6.75B
FCF Margin
+81.4%
Cash flow waterfall for Thermo Fisher Scientific (TMO) — TTM through Q1 2026
Free cash flow: $6.75B
Cash flow breakdown for Thermo Fisher Scientific (TMO) — TTM through Q1 2026
| Line item | Amount | Running total |
|---|---|---|
| Operating Cash Flow | $8.29B | $8.29B |
| Capital Expenditure | −$1.54B | $6.75B |
| Free Cash Flow | $6.75B | $6.75B |
| Acquisitions | −$12.91B | −$6.16B |
| Other Investing | $1.97B | −$4.19B |
| Share Buybacks | −$4.00B | −$8.19B |
| Dividends Paid | −$649.00M | −$8.84B |
| Net Debt Change | $2.21B | −$6.63B |
| Other Financing | $5.43B | −$1.20B |
| Forex Effect | $307.00M | −$891.00M |
| Net Cash Decrease | −$892.00M | −$892.00M |
- Operating Cash Flow$8.29B
- Capital Expenditure−$1.54B
- Free Cash Flow$6.75B
- Acquisitions−$12.91B
- Other Investing$1.97B
- Share Buybacks−$4.00B
- Dividends Paid−$649.00M
- Net Debt Change$2.21B
- Other Financing$5.43B
- Forex Effect$307.00M
- Net Cash Decrease−$892.00M
Want to see what drove the FCF change?Free Cash Flow Bridge
Frequently asked questions
Data & methodology
Thermo Fisher Scientific (TMO) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement